Kalaris and AlloVir Announce Stockholder Approval of Merger Combined company expected to trade on Nasdaq under “KLRS” after closing PALO ALTO, Calif. and LEXINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent diseases of the retina, and AlloVir, Inc. (Nasdaq: ALVR) announced today the results for the proposals voted upon by AlloVir stockholders at a Special Meeting of Stockholders held on March 12, 2025. The AlloVir stockholders ...
Occidental Announces Offer to Exercise Warrants at a Temporarily Reduced Price HOUSTON, March 03, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced an offer to exercise its outstanding publicly traded warrants (the “Warrants”) at a temporarily reduced price (the “Offer”). The Offer is available to holders of the Warrants, each representing the right to purchase one share of Occidental’s common stock, $0.20 par value per share, at an exercise price of $22.00. The Warrants were initially distributed by Occidental on August 3, 2020 in the form of a dividend to the holders of record of O...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Occidental Announces Further Progress on Debt Reduction Achieved near-term debt repayment target of $4.5 billion in the fourth quarter of 2024Announced proceeds from $1.2 billion of divestitures signed in the first quarter of 2025 will go toward current year debt maturities HOUSTON, Feb. 18, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced it achieved its near-term debt repayment target of $4.5 billion in the fourth quarter of 2024 and signed two agreements in the first quarter of 2025 to divest upstream assets to undisclosed buyers for a combined total of $1.2 billion. The divesti...
Occidental Announces Fourth Quarter 2024 Results HOUSTON , Feb. 18, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its fourth quarter 2024 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website, . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Wednesday, February 19, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (internat...
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs – Company halting further development of imvotamab (CD20 x CD3) and IGM-2644 (CD38 x CD3) – – Company reducing its workforce by 73% – – Cash and investments of $183.8 million (unaudited) as of December 31, 2024 – MOUNTAIN VIEW, Calif., Jan. 09, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic update to halt further development of imvotam...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.